Zobrazeno 1 - 10
of 191
pro vyhledávání: '"W. Dahut"'
Autor:
Z Blake, D Nemirovsky, J Enders, A Pillai, M Rothberg, J Noun, W Dahut, F Karzai, P Pinto, B Turkbey, S Gurram
Publikováno v:
The Journal of Sexual Medicine. 20
Introduction Low serum testosterone (T) in the presence of clinical symptoms of hypogonadism is essential in determining who may benefit from T replacement therapy. However, clinical symptoms associated with hypogonadism are non-specific and challeng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bcc55d663ea16291d8de15024beb91c
https://doi.org/10.1093/jsxmed/qdad060.279
https://doi.org/10.1093/jsxmed/qdad060.279
Autor:
R.A. Madan, R. Donahue, Y-T. Tsai, F. Karzai, S. Gandhy, M. Bilusic, P. Arlen, M. Theoret, J. Marte, L. Cordes, A. Couvillon, A. Hankin, M. Williams, S. McMahon, W.D. Figg, W. Dahut, J. Schlom, J. Gulley
Publikováno v:
Annals of Oncology. 33:S1191
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1e02c21e10a0df15c282edf07d6a738
https://doi.org/10.1016/j.annonc.2022.07.1898
https://doi.org/10.1016/j.annonc.2022.07.1898
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Chromatography B. 811:135-141
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b726c278c4288a0b5e5a9d0e95a82988
https://doi.org/10.1016/s1570-0232(04)00666-x
https://doi.org/10.1016/s1570-0232(04)00666-x
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P, Bhargava, J L, Marshall, W, Dahut, N, Rizvi, N, Trocky, J I, Williams, H, Hait, S, Song, K J, Holroyd, M J, Hawkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(12)
A Phase I study of squalamine, a novel antiangiogenic agent originally isolated from the dogfish shark Squalus acanthias, was conducted in patients with advanced cancers to: (a) determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43616d047fed5e3fe33527d57d9e7803
https://pubmed.ncbi.nlm.nih.gov/11751482
https://pubmed.ncbi.nlm.nih.gov/11751482
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 42(9)
Several studies have found that administration of etidronate results in competitive interference with 99mTc-labeled bone scanning reagents. In contrast, in other studies this problem was not encountered with other bisphosphonates.We prospectively stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6b665ccf6317be4e0c9a074df07737ae
https://pubmed.ncbi.nlm.nih.gov/11535725
https://pubmed.ncbi.nlm.nih.gov/11535725
Autor:
W D, Figg, W, Dahut, P, Duray, M, Hamilton, A, Tompkins, S M, Steinberg, E, Jones, A, Premkumar, W M, Linehan, M K, Floeter, C C, Chen, S, Dixon, D R, Kohler, E A, Krüger, E, Gubish, J M, Pluda, E, Reed
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(7)
Thalidomide is a potent teratogen that causes dysmelia in humans. Recently, in vitro data suggested that it inhibits angiogenesis. Prostate cancer is dependent on the recruitment of new blood vessels to grow and metastasize. Based on those data, we i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::373d65a32e0ce6b7493fd0f647c4fdd0
https://pubmed.ncbi.nlm.nih.gov/11448901
https://pubmed.ncbi.nlm.nih.gov/11448901
Publikováno v:
Archives of dermatology. 137(4)
Anti-angiogenesis is an exciting new approach to anticancer therapy. COL-3, a tetracycline derivative, is a novel anti-angiogenesis agent with potent preclinical anticancer activity. During the conduct of a phase 1 clinical trial for refractory metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7299d5336787b7dec7e88044dc26ae2
https://pubmed.ncbi.nlm.nih.gov/11295928
https://pubmed.ncbi.nlm.nih.gov/11295928